Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28790479 | 0.80 | CYP2C19 (0.52) | ALDH1A1HTTHRH3KDM4EGAA | |
| SCHEMBL6555500 | 0.79 | NPC1 (0.47) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 | |
| SCHEMBL19145771 | 0.79 | SMN1; SMN2 (0.47) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 | |
| SCHEMBL13156073 | 0.79 | SMN1; SMN2 (0.46) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 | |
| SCHEMBL31010224 | 0.78 | CYP2C19 (0.55) | ALDH1A1HTTHRH3KDM4EGAA | |
| SCHEMBL6033433 | 0.78 | CXCR4 (0.45) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 | |
| SCHEMBL31426439 | 0.77 | CXCR4 (0.66) | CXCR4ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL1054071 | 0.77 | CXCR4 (0.66) | CXCR4ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL465756 | 0.77 | CXCR4 (0.47) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 | |
| SCHEMBL3512357 | 0.77 | CXCR4 (0.47) | CXCR4ALDH1A1MEN1KMT2ACYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107148420-A | Benzyl substituted indazoles | 拜耳制药股份公司 | 2017-09-08 | — | — | CN | claimed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-104903320-B | Nitrogen-containing heterocycle compound or its salt | 富士胶片株式会社 | 2018-11-13 | — | — | CN | disclosed |
| WO-2018086589-A1 | 1,5,7-TRI-SUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES | 上海海雁医药科技有限公司 | 2018-05-17 | — | — | WO | disclosed |
| CN-107148420-A | Benzyl substituted indazoles | 拜耳制药股份公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-102227420-A | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| EP-1056771-B1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-11-30 | — | — | EP | disclosed |
| EP-1056771-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043699-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | CXCR4 4588/4885ALDH1A1 3827/4885MEN1 2242/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | CXCR4 4588/4885ALDH1A1 3827/4885MEN1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.